ArticleBMC ophthalmology2025
One-year outcomes of a trifocal intraocular lens with glistening-free hydrophobic acrylic using the mix-and-match technique.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A One-Year Visual and Safety Evaluation of a Newly Available Trifocal Intraocular Lens in Patients With Bilateral Cataracts: Clinical Outcomes From a Prospective Study.Journal of ophthalmology · 2026Article
- Visual Outcomes and Patient Satisfaction with Extended Monovision-An Innovative Strategy to Achieve Spectacle Independence in Refractive Lens Exchange.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThe Clareon PanOptix (CNWT) IOL is a newer trifocal IOL made from a glistening-free hydrophobic acrylic material incorporating hydroxyethyl methacrylate (HEMA). While its predecessor (TFNT) has established clinical outcomes, long-term data. This study aimed to evaluate the refractive and visual outcomes during a 1-year follow-up after CNWT implantation in one eye, with a different type of refractive multifocal or extended depth of focus IOL in the contralateral eye (mix- and match setting).
methodThis was a retrospective, single-arm case series conducted at the single eye clinic, Seoul, Republic of Korea. The study included patients who underwent cataract surgery with mix-and-match IOL implantations, receiving a CNWT in one eye. Data were collected from the eyes with a CNWT. Monocular uncorrected distance visual acuity (UCDVA), corrected distance visual acuity (CDVA), uncorrected near visual acuity (UCNVA), and manifest refraction were analyzed from measurements taken at 1, 3, 6, and 12 months postoperatively. Rates and causes of secondary surgical intervention, such as IOL exchange and toric IOL axis readjustment, were also investigated. Statistical analysis involved Kolmogorov-Smirnov tests for normality and t-tests for comparisons, with p <.05 considered significant.
resultsData from 897 eyes (out of 1282 initially screened) with continuous measurements and no secondary interventional surgeries were included in the primary monocular visual acuity and refractive analysis. UCDVA of LogMAR 0.0 or better increased from 50.91% at 1 month to 85.95% at 12 months. CDVA of LogMAR 0.0 or better improved from 89.52% at 1 month to 98.1% at 12 months. At 12 months, 94.09% of eyes achieved UCNVA of LogMAR 0.1 or better. A slight mean hyperopic shift (+ 0.07D) was observed up to 12 months. Toric CNWT IOLs were used in 71.0% of these eyes, with 88.07% achieving manifest refractive astigmatism of ≤ -0.75D at 12 months. Overall, 85 out of 1282 eyes (6.63%) underwent secondary surgery: 4.45% for IOL exchange and 2.18% for toric IOL axis readjustment. Post-reoperation, UCDVA and UCNVA significantly improved.
conclusionsThe new hydrophobic acrylic trifocal IOL (CNWT) with HEMA demonstrated significant improvements in visual acuity and stable refractive outcomes over one year in a mix-and-match setting. The use of toric CNWT IOLs effectively reduced astigmatism. These findings suggest that this IOL is a reliable option for enhancing visual quality and reducing spectacle dependency in this specific implantation context. Despite the low rate of reoperations, the results underscore the ongoing need for advancements in biometric measurements and IOL power calculation formulas to further minimize such interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.